Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Hetrombopag on Rosuvastatin PK in Healthy Subjects
NCT05088343Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hetrombopag in immune thrombocytopenia (ITP) and aplastic anemia, sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration vs Time Curve (0-72h) and 1 more. Started Sep 2020; status: completed.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)aplastic anemia
Beyond the preview
Go deeper on NCT05088343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088343.